featured
HR+ Metastatic Breast Cancer Survival Outcomes Before and After CDK4/6 Inhibitor Introduction in the US
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer
Breast Cancer Res Treat 2024 Aug 23;[EPub Ahead of Print], A Brufsky, ML Kwan, R Sandin, S Stergiopoulos, S Karanth, AS Cha-Silva, D Makari, RK GoyalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.